一财记者现场直击高值耗材集采开标，双重复活机制如何生效

Core Insights - The sixth batch of national organized high-value medical consumables centralized procurement includes 12 types of medical consumables, specifically drug-coated balloons and urological intervention products [1][3][12] - A total of 227 companies submitted bids for 496 products, with 202 companies winning bids for 440 products, indicating a diverse supply for medical institutions [1][12] Group 1: Procurement Details - The procurement process took place in Tianjin, lasting 11 hours, with the results announced the following day [1][7] - The drug-coated balloons are further categorized into coronary and peripheral vascular types, marking the second centralized procurement in the cardiovascular field after coronary stents [3][12] - Urological high-value consumables are entering centralized procurement for the first time, with specific categories including ureteral intervention guidewires and balloon dilation catheters [4][12] Group 2: Competitive Landscape - The most competitive item in this procurement was the ureteral intervention guidewire, with 122 companies competing, while the least competitive was the peripheral vascular drug-coated balloon, with only 3 companies [12] - The introduction of "anchor pricing" aims to prevent irrational bidding and enhance the selection of clinical options [12][13] Group 3: Impact on Healthcare - The centralized procurement is expected to improve patient access to treatments and reduce costs for established products, allowing more new drugs and consumables to enter clinical use [13] - The initiative is anticipated to drive medical companies to innovate and enhance supply quality through technological advancements [13]